CAL-101 is a potent PI3K p110¦Ä inhibitor with an IC50 of 65 nM. CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. CAL-101 has 40 to 300-fold selectivity compared to other PI3K isoforms. In vitro studies of 0.1 to 10 µM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.

June 21, 2017

prudect name : CAL-101 is a potent PI3K p110¦Ä inhibitor with an IC50 of 65 nM. CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. CAL-101 has 40 to 300-fold selectivity compared to other PI3K isoforms.
In vitro studies of 0.1 to 10 µM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.
CAL-101

Synonyms: CAS NO: 870281-82-6Molecular Formula: C₂₂H₁₈FN₇OMolecular Weight: 415.42Purity: 98% minSolubility: In DMSOStorage: −20°C

BAL-4815 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18508680